Medical Marijuana and CBD for Insomnia: Do Cannabis Products Help Treat Sleep Disorders? Does CBD and THC Help with Sleep?

Insomnia is one of the most common reasons people self-medicate with cannabis. The question is whether the evidence keeps pace with this practice. The answer is less impressive than product descriptions suggest: a systematic review of 14 preclinical and 12 clinical studies states plainly that the evidence is insufficient today to recommend cannabinoids for routine treatment of any sleep disorder (Suraev et al., 2020). This does not mean nothing is known. Enough is known to separate THC from CBD, describe what each does to the architecture of the night, and show where supplements end and sleep medicine begins. This text organizes mechanisms, study data, dosing, drug interactions, and the Polish legal status. It also shows how CBD is combined with other sleep supplements and what to do if the preparation does not work.

KEY INFORMATION
• In a retrospective series of 72 patients, sleep improved in 48, i.e., 66.7%, in the first month, but the result fluctuated over time (Shannon et al., 2019).
• Polysomnography in 27 healthy volunteers showed no significant effect after 300 mg CBD; the authors state that CBD does not disrupt normal sleep architecture (Linares et al., 2018).
• Single-dose THC is sometimes associated with increased slow-wave sleep and decreased REM, but the effect does not persist with chronic use (Kaul et al., 2021).
• CBT-I therapy is the initial treatment for chronic insomnia with a strong recommendation from the American College of Physicians (Qaseem et al., 2016).
• WHO states that CBD shows no signs of abuse potential or dependence in humans (WHO ECDD, 2018).

Do CBD and THC help with sleep?

Cautiously and variably. CBD has case series suggesting sleep improvement in insomnia with an anxiety component, but in a controlled polysomnographic study it changed nothing measurable. THC can act faster, but its effect on night structure weakens with chronic use.

The most often cited clinical work is a retrospective analysis of records of 72 adult psychiatric outpatients. Sleep improved in the first month in 48 of them, i.e., 66.7%, anxiety decreased in 57, i.e., 79.2%. The authors note, however, that the sleep result fluctuated in subsequent months, and the study was not randomized (Shannon et al., 2019). This is a practice observation, not proof of efficacy.

On the other side is a double-blind crossover study in which 27 healthy volunteers received 300 mg CBD or placebo half an hour before an eight-hour polysomnographic recording. The drug caused no significant effect, and the authors conclude that CBD does not disrupt normal sleep architecture (Linares et al., 2018). This statement means something different than “improves sleep” but is often cited as if it meant the same.

The difference between these results is not a contradiction. The first study included patients with anxiety and disturbed sleep, the second healthy people with nothing to improve. Babson’s review summarizes this state in one sentence: research on cannabis and sleep is in its infancy and yields mixed results (Babson et al., 2017).

When does insomnia stop being just a bad night?

When difficulties falling asleep or maintaining sleep occur at least three times a week for at least three months and cause daytime consequences (Drager et al., 2023). The latter condition is often overlooked, and without it, there is no diagnosis.

Diagnostic guidelines list daytime consequences including fatigue, decreased energy, poorer attention, concentration and memory, and mood changes such as irritability and depression (Drager et al., 2023). The number of hours slept alone does not decide. A person sleeping six hours and functioning well does not have insomnia; a person sleeping seven and waking up feeling broken may have it.

This distinction has practical consequences. Situational insomnia caused by a specific event usually resolves on its own within weeks and rarely requires pharmacology. Chronic insomnia is a separate diagnosis with its own treatment, and a supplement is not that treatment. Guidelines place cognitive-behavioral therapy here, not an evening preparation.

It is also worth separating primary from secondary insomnia. The latter accompanies another disease: depression, anxiety disorders, chronic pain, sleep apnea, or thyroid diseases. If the cause lies underneath, working on falling asleep alone gives a false effect and delays proper diagnosis. More about natural sleep methods can be found in the post on adult insomnia and non-sedative methods.

How is the night structured and why does the body need sleep phases?

Sleep is not a homogeneous state. In healthy adults, it passes sequentially through NREM stages from N1 to N3, then REM appears, roughly at the ninetieth minute of sleep (Edwards et al., 2010). With seven to eight hours of sleep, the cycle repeats four to five times.

The distribution of phases at night is uneven. Early cycles are richer in deep N3 sleep, later ones in REM. Therefore, shortening the night by two hours does not equally remove everything but mainly cuts REM, while going to bed earlier at the same wake-up time adds mostly deep sleep.

Why this breakdown in a text about cannabinoids? Because the question “does something help with sleep” is incomplete. A substance may shorten sleep latency and simultaneously impoverish the phase responsible for memory. The assessment differs when looking at subjective feeling of restfulness versus polysomnographic recording. The rest of this text adheres to the latter criterion wherever data allow.

How does the endocannabinoid system participate in sleep regulation?

CB1 receptors are distributed in the central nervous system, including structures involved in wakefulness regulation, and these are the direct target of THC. CBD acts differently, and this is one of the most frequently misrepresented points in consumer texts.

A systematic review of cannabidiol molecular targets states that CBD does not directly interact with the endocannabinoid system outside in vitro conditions at supraphysiological concentrations, and it is very unlikely that its action in neurological diseases occurs through this system (Ibeas Bih et al., 2015). Over 65 distinct molecular targets have been described for CBD, most of which the review authors rejected as unconvincing.

The statement “CBD inhibits anandamide breakdown and therefore induces sleep” is a simplification functioning as fact in store texts. FAAH enzyme inhibition was described in laboratory conditions, but translation to a sedative effect in humans has not been demonstrated. This is important because the whole mechanism is often presented as established, but it is a hypothesis.

What remains in practice? That THC has a clear binding point, and CBD does not have one. Kaul’s review describes the modulatory effect of cannabinoids on sleep physiology while noting small samples and bias risk in most studies (Kaul et al., 2021). More about how cannabis interacts with circadian rhythm is in the post on cannabis effects on sleep.

How does THC affect sleep short- and long-term?

Single THC administration is sometimes associated with increased slow-wave sleep and decreased REM, but the effect on slow-wave sleep and total sleep time is not lasting. With chronic use, the picture reverses: slow-wave sleep decreases, sleep latency lengthens, awakenings increase (Kaul et al., 2021).

The controlled study version is even more cautious. In a four-way crossover in eight healthy volunteers, 15 mg THC had no effect on nocturnal sleep in EEG recording. Effects appeared only the next morning: worse memory, shorter sleep latency, and greater sleepiness reported by participants (Nicholson et al., 2004). The popular statement that THC prolongs N3 phase thus lacks unequivocal support.

Sleep is a frequent motive for self-medication. In a study of 170 patients at a Californian medical cannabis clinic, people with high PTSD scores used cannabis more often specifically to improve sleep and used it more frequently than others (Bonn-Miller et al., 2014). The authors ask whether alternative sleep improvement methods might reduce this dependence.

What does polysomnography say about CBD and sleep architecture?

It says something very specific and it is not a promise of efficacy. After 300 mg CBD, an anxiolytic dose, an eight-hour polysomnographic recording in healthy volunteers did not differ significantly from placebo. The authors conclude: CBD does not alter normal sleep architecture (Linares et al., 2018).

This is a safety statement, not an efficacy one. It distinguishes CBD from benzodiazepines and antidepressants, which alter sleep structure, but does not prove that CBD helps anyone fall asleep. The study included healthy people and measured one night after one dose.

The oldest clinical data come from the 1970s and 1980s. In a trial of 15 people with insomnia, 40, 80, and 160 mg CBD were compared with placebo and 5 mg nitrazepam. Only the 160 mg group reported significantly longer sleep than placebo; at all three doses, participants recalled dreams less often (Carlini and Cunha, 1981). Remember the proportion: the dose at which anything shifted was many times higher than typical supplement doses.

Separately, a case of a ten-year-old girl with post-traumatic stress disorder was reported, where CBD oil brought sustained anxiety reduction and gradual improvement in sleep quality and quantity (Shannon and Opila-Lehman, 2016). This is one patient, so the evidence weight is low, though the direction matches the 72-case series. A summary of cannabis and sleep studies is expanded in the post on CBD in treating insomnia and other sleep disorders.

Do CBN and terpenes really induce sleep?

The thesis of cannabinol as a “sleep cannabinoid” lacks clinical support in humans today. CBN forms from THC oxidation in aging raw material, and the belief in its sedative strength derives from observations of aged flower, not controlled trials.

A systematic review of cannabinoids in sleep disorders finds no basis for routine use of any, and most included studies are rated as having moderate or high risk of bias (Suraev et al., 2020). CBN is not an exception but a particularly poorly studied fragment.

Terpenes are similar but more interesting. Russo’s review describes myrcene, linalool, and beta-caryophyllene as compounds with real pharmacological activity, present in diet and considered safe, and hypothesizes synergy with cannabinoids. The author states explicitly synergy “if proven,” not a confirmed phenomenon (Russo, 2011).

The practical conclusion is inconvenient for labels. The declaration “CBN sleep oil” describes composition, not confirmed effect. If the producer provides a terpene profile in the certificate of analysis, you get more product information but still no proof that this blend will lengthen your night.

How does CBD compare to sleeping pills and melatonin?

It appears as a substance with a good safety profile and weakly documented sedative efficacy. Sleeping pills have the opposite set of pros and cons, and melatonin gives a small but measured effect in meta-analysis. The choice depends on what exactly spoils your night.

The melatonin meta-analysis included 19 studies and 1683 people with primary sleep disorders. A seven-minute latency reduction sounds disappointing, but authors note the effect does not fade with continued use, unlike many sleeping pills (Ferracioli-Oda et al., 2013). Melatonin addresses a different problem than CBD: it regulates the clock, not calms tension.

If your night is spoiled by jet lag or shift work, melatonin is a more sensible starting point; in chronic insomnia alone, AASM guidelines recommend against its use (Sateia et al., 2017). If the source is evening racing thoughts, none of these agents replaces stimulus control and rhythm work described by CBT-I.

Which drugs interact with CBD?

Primarily those metabolized by the liver. A cannabinoid pharmacokinetics review indicates possible interactions via enzyme and transporter inhibition or induction, citing inhibition of clobazam metabolism by CBD as an example (Lucas et al., 2018).

The same review warns about pharmacodynamic interactions. Cannabis combined with other central nervous system depressants adds sedation, and combining with sympathomimetic drugs may increase hypertension and tachycardia. Older adults are listed as a group at increased risk of adverse effects despite potential symptomatic benefits.

Iffland’s safety review confirms CBD’s favorable profile but notes that CBD’s effects on liver enzymes, drug transporters, and interactions require further clinical research (Iffland and Grotenhermen, 2017). The most commonly reported symptoms are listed in the section on CBD adverse effects below.

WHO’s report aligns with this cautiously: CBD is generally well tolerated with a good safety profile, and reported adverse effects may result from interactions with medications the patient already takes (WHO ECDD, 2018). The practical conclusion is simple: if you take anything regularly, inform your doctor before introducing CBD instead of deciding alone.

What adverse effects does CBD cause?

The best documented symptom is diarrhea. In a meta-analysis of randomized placebo-controlled trials including 12 studies and 803 participants, excluding pediatric epilepsy studies, the only adverse effect significantly associated with CBD was diarrhea (Chesney et al., 2020).

This distinction is important because it changes the meaning of the whole list. In the full set, CBD was also associated with somnolence, sedation, decreased appetite, more frequent study withdrawal, and abnormal liver tests. Associations with somnolence and abnormal liver tests were limited to pediatric epilepsy studies where CBD was combined with clobazam or valproate, at doses incomparable to supplement doses.

Iffland’s safety review lists fatigue, diarrhea, and appetite and weight changes as the most common reported symptoms and notes that compared to drugs used for the same indications, CBD’s profile is better (Iffland and Grotenhermen, 2017). However, some toxicological parameters, such as effects on hormonal balance, remain unstudied.

Conclusions for someone wanting to take CBD in the evening long-term are twofold. First, data come mainly from short trials, and chronic administration in adults without epilepsy is poorly studied. Second, the most serious signals appeared where CBD was combined with other drugs, so it is the combination, not the preparation itself, where caution is warranted.

How to dose CBD for insomnia?

The principle from the pharmacokinetic review is “start low and go slow,” carefully observing desired and adverse effects (Lucas et al., 2018). No daily doses for insomnia have been established because no studies have determined them.

It is worth knowing the dose range from studies cited in consumer texts. In the 72-case series, almost all patients received 25 mg CBD daily in capsules, a few 50 or 75 mg, and one person’s dose was gradually increased to 175 mg (Shannon et al., 2019). The often repeated “25 to 175 mg” thus describes extremes, not a typical dose.

Numbers in the last column come from a systematic review of CBD pharmacokinetics in humans (Millar et al., 2018). The authors emphasize limited and sometimes conflicting data. Popular tables giving exact bioavailability percentages for oral and sublingual routes are not supported by this work because such measurements in humans have not been performed.

Practically, this means one thing: keep a sleep diary and change one thing at a time.

How to combine CBD with other sleep supplements?

Cautiously and with lower expectations than “sleep stack” sets sold suggest. The two most common ingredients in such sets, melatonin and valerian, have AASM guidelines recommending against their use in chronic insomnia (Sateia et al., 2017).

This does not mean combining never makes sense. It means no studies have compared CBD with melatonin versus CBD alone and shown the combination’s superiority. Claims of synergy come from product descriptions, not clinical trials, and should be treated as such when making purchase decisions. The same AASM recommendation covers tryptophan and diphenhydramine, common ingredients in over-the-counter evening sets.

Safety of combinations is a separate matter, and here data are more concrete. Summation of sedation and interactions via liver enzymes are described above in the section on drugs interacting with CBD. Alcohol as an “enhancer” of evening calm is excluded for the same reason, though this is a mechanistic inference, not a finding from cited studies: none included alcohol.

If you still want to test stacks, do so methodically: add one ingredient at a time and allow at least two weeks to assess before adding another.

When CBD does not work and what to do then?

The most important case is obstructive sleep apnea. The American Academy of Sleep Medicine states that medical cannabis and its synthetic extracts should not be used to treat apnea due to unreliable administration methods and insufficient evidence of efficacy, tolerance, and safety (Ramar et al., 2018).

The position goes further than usually cited. AASM calls for removing apnea from the list of conditions qualifying for medical cannabis programs and notes that cannabinoid composition in products is variable and unregulated. The only agent with any data here is dronabinol from small pilot studies, where most patients reported sleepiness.

The practical conclusion is simple: suspected apnea is a reason for diagnosis, not changing the preparation. Symptoms indicating apnea are listed below in the section on when insomnia requires a doctor’s visit.

There are also conditions where cannabinoids should not be used regardless of sleep quality. The pharmacokinetic review indicates cannabis use is contraindicated in significant psychiatric and cardiovascular diseases, as well as serious kidney or liver diseases (Lucas et al., 2018).

If after several weeks nothing changes, it is worth reversing the intuitive order of actions. First check if insomnia is secondary to another disease. Then try cognitive-behavioral therapy, which guidelines place first. Increasing supplement dose is the least justified step on this list.

Why is CBT-I first-line treatment?

Because that is the highest strength recommendation in guidelines. The American College of Physicians recommends that every adult patient with chronic insomnia receive cognitive-behavioral therapy as initial treatment; this is a strong recommendation based on moderate-quality evidence (Qaseem et al., 2016).

Pharmacotherapy appears only as a second step, and conditionally. ACP recommends shared decision-making with the patient after discussing benefits, harms, and costs of short-term drug use in those for whom CBT-I alone was ineffective. The recommendation is weak, and evidence is low quality.

Brazilian guidelines from 2023 formulate this even more strongly, calling multicomponent CBT-I the gold standard for chronic insomnia treatment (Drager et al., 2023). Therapy includes stimulus control, sleep restriction, relaxation techniques, work on sleep beliefs, and education.

From this framework, there is a place for cannabinoids, but it is not the first place. A supplement may reduce evening tension enough to facilitate behavioral techniques but will not replace them or diagnosis. Reversing this order is the most common mistake of people trying to manage insomnia on their own.

When does insomnia require a doctor’s visit?

Always when it meets chronic insomnia criteria, i.e., persists at least three months, occurs at least three nights a week, and worsens daytime functioning (Drager et al., 2023). Self-treatment of such a state with supplements delays diagnosis of the cause.

There are also symptoms directing to a specialist regardless of duration. Loud snoring with breathing pauses and morning headaches suggest obstructive sleep apnea, which CBD will not improve because the problem is mechanical. Excessive daytime sleepiness despite sufficient sleep hours, unpleasant leg sensations before sleep, and recurring nightmares also require diagnosis.

It is useful to know what the doctor uses. The basis is history and a sleep diary kept for one to two weeks, supplemented by insomnia severity questionnaires. Polysomnography is not routine for insomnia; it is performed when apnea, parasomnias, or other disorders requiring recording are suspected.

A separate category is secondary insomnia due to disease that must be treated first. Depression, anxiety disorders, hypothyroidism or hyperthyroidism, iron deficiency, and chronic pain can fully explain disturbed sleep. In such cases, night improvement comes with treating the cause, not separately.

What is the legal status of medical marijuana and CBD in Poland?

Products containing THC are dispensed in Poland only by prescription, and outside this mode, trade in cannabis other than fiber hemp remains prohibited. Cannabidiol is in a different situation: the word “cannabidiol” does not appear in controlled substance lists even once.

The threshold distinguishing fiber hemp from others is 0.3% dry mass, counted as the sum of delta-9-THC and tetrahydrocannabinolic acid, rounded to one decimal place. The basis is Article 4 point 5 of the Act of July 29, 2005 on counteracting drug addiction (consolidated text Journal of Laws 2023 item 1939), as amended by the Act of March 24, 2022 (Journal of Laws 2022 item 763), effective May 7, 2022.

This distinction changes the laboratory test result, so it is not a formality. The threshold concerns the sum of two compounds, not just delta-9-THC, which for plant raw material gives values clearly higher than measuring one fraction. Until May 6, 2022, the national threshold was 0.20%, so older texts give a different number.

It is worth correcting one more repeated sentence. The Polish threshold corresponds to the EU threshold of 0.3% from Regulation (EU) 2021/2115 but does not derive from it: these are two separate regulations with the same numeric value. The earlier Regulation 1307/2013, cited in many articles, set 0.2% and was repealed on January 1, 2023.

What does this mean for the reader?

The picture is less clear than product descriptions suggest, and this is the most honest conclusion of this text. A systematic literature review finds no basis for routine cannabinoid use in sleep disorder treatment, and most available studies are rated as having bias risk (Suraev et al., 2020).

Three things are worth remembering. CBD at an anxiolytic dose does not disrupt normal sleep architecture, which argues for safety, not efficacy. THC acts faster, but its effect on night structure reverses with chronic use. Chronic insomnia has its own treatment with a strong recommendation, and it is not any evening preparation.

If you still want to try, do it methodically: one change at a time, lowest reasonable dose, sleep diary for at least two weeks, and talk to your doctor if you take anything regularly. Without this, you cannot distinguish the preparation’s effect from normal night variability.

Separately, it is worth guarding the boundary between supplement and drug. THC products require a prescription in Poland, and CBD sold without prescription is not registered as a medicinal product for insomnia treatment. If a seller describes a preparation as a drug, that is a warning sign about the seller, not product information.

Finally, often omitted in sleep supplement texts: the improvement you seek usually does not come from one substance but from changing several conditions at once: a fixed wake-up time, limiting time spent in bed awake, and giving up weekend catch-up sleep. These are elements of cognitive-behavioral therapy, not lifestyle advice, and have the strongest recommendation of everything described in this text.

Frequently Asked Questions

Does CBD help with insomnia?

The data are inconclusive. In a retrospective series of 72 patients, sleep improved in 66.7% during the first month, but the result fluctuated over time, and the study was not randomized (Shannon et al., 2019). A systematic review finds no basis for routine use of cannabinoids in sleep disorders (Suraev et al., 2020).

What CBD dose for sleep is supported by research?

No established dose exists. In the series of 72 cases, almost all received 25 mg per day, a few 50 or 75 mg, and one person up to 175 mg (Shannon et al., 2019). In an older trial in people with insomnia, longer sleep was reported only by the group taking 160 mg (Carlini and Cunha, 1981).

Does THC help to fall asleep?

Short-term it is sometimes associated with increased slow-wave sleep and decreased REM, but the effect does not persist chronically, and with regular use slow-wave sleep decreases and awakenings increase (Kaul et al., 2021). In Poland, THC products are dispensed only by prescription.

Does CBD alter sleep phases like THC?

Not in available polysomnographic recordings. After 300 mg CBD in 27 healthy volunteers, no significant differences compared to placebo were found, and the authors state that CBD does not disrupt normal sleep architecture (Linares et al., 2018). This is a safety conclusion, not an efficacy one.

Is CBD addictive?

The WHO Expert Committee report states that CBD shows no signs of abuse potential or dependence in humans and is generally well tolerated (WHO ECDD, 2018). Reported adverse effects may result from interactions with concurrently taken medications.

Which drugs interact with CBD?

Primarily those metabolized in the liver. A pharmacokinetic review indicates possible interactions through enzyme and transporter inhibition, citing inhibition of clobazam metabolism by CBD as an example (Lucas et al., 2018). Combining with central nervous system depressants adds sedation.

Can CBD be given to a child with insomnia?

Only under medical supervision. A case of a ten-year-old patient with post-traumatic stress disorder was described, where CBD oil reduced anxiety and gradually improved sleep quality and quantity (Shannon and Opila-Lehman, 2016). This is a single case report and not a basis for parental self-decision.

Does CBD replace CBT-I therapy?

It does not replace it. The American College of Physicians recommends cognitive-behavioral therapy as the initial treatment for chronic insomnia in all adult patients, with the highest strength recommendation (Qaseem et al., 2016). Pharmacotherapy is considered only after unsuccessful CBT-I.

If after reading you want to compare available preparations, visit the hemp oils section.

This article is for informational and educational purposes and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-09-22